Patent search ap:("FORMA Therapeutics Page Inc.") AND inv:"Jennifer R. Thomason"

1.

发明授权
Methods using HDAC11 inhibitors 有权

公开(公告)号：US10508088B2

公开(公告)日：2019-12-17

申请号：US16202207

申请日：2018-11-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Jennifer Lee , Nicholas Barczak , Jaime A. Escobedo , Chiara Conti , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Xiaozhang Zheng

IPC: C07D263/58 , A61P35/00 , A61K31/403 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/4709 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07C53/06 , C07D209/40 , C07D209/54 , C07D221/20 , C07D235/30 , C07D277/82 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D473/00 , C07D487/04 , C07D491/056 , C07D491/107 , C07D498/04

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

2.

发明授权
3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors 有权

公开(公告)号：US10457652B2

公开(公告)日：2019-10-29

申请号：US16219648

申请日：2018-12-13

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair , David S. Millan , Matthew W. Martin

IPC: A61K31/5513 , C07D243/14 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D413/06 , C07D417/06 , C07D267/14 , C07D413/12 , C07D413/04 , C07D291/08 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

3.

发明申请
3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开

公开(公告)号：US20190119228A1

公开(公告)日：2019-04-25

申请号：US16219592

申请日：2018-12-13

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair , David S. Millan , Matthew W. Martin

IPC: C07D267/14 , C07D413/04 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

4.

发明授权
Alpha-cinnamide compounds and compositions as HDAC8 inhibitors 有权

公开(公告)号：US10266487B2

公开(公告)日：2019-04-23

申请号：US15925559

申请日：2018-03-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng

IPC: C07C259/06 , C07D209/46 , C07D213/75 , C07D213/81 , C07D215/12 , C07D317/68 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D333/70 , C07D401/04 , C07D401/12 , C07D235/30 , C07D239/20 , C07D239/22 , C07D405/12 , C07D409/04 , C07D409/12 , C07D241/12 , C07D417/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D401/14 , C07D487/04 , C07D487/08 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D491/10 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , A61K31/407 , A61K31/5377 , C07D495/10 , A61K31/185 , A61K31/438 , A61K31/277 , C07D209/44 , A61K31/4035 , C07D295/155 , A61K31/451 , C07D471/10 , A61K31/435 , C07D487/10 , C07D221/20 , A61K31/397 , C07D235/14 , A61K31/4184 , C07D233/68 , A61K31/417 , C07D213/56 , A61K31/44 , C07D241/08 , A61K31/495 , C07D417/04 , A61K31/4439 , C07D471/04

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

5.

发明申请
3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 审中-公开

公开(公告)号：US20190112283A1

公开(公告)日：2019-04-18

申请号：US16218132

申请日：2018-12-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , David S. Millan , Matthew W. Martin , Kenneth W. Bair

IPC: C07D267/14 , C07D413/04 , C07D267/12 , C07D413/06 , C07D401/06 , C07D417/04 , C07D471/04 , C07D498/04 , C07D243/14 , C07D291/08 , C07D498/08 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D495/10 , C07D491/107 , C07D413/08 , C07D493/08 , C07D413/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

6.

发明授权
3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors 有权

公开(公告)号：US10239845B2

公开(公告)日：2019-03-26

申请号：US15013816

申请日：2016-02-02

Applicant: Forma Therapeutics, Inc.

Inventor： Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin

IPC: A61K31/553 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10 , C07D267/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

7.

发明申请
ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS 审中-公开

公开(公告)号：US20180297939A1

公开(公告)日：2018-10-18

申请号：US15925559

申请日：2018-03-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng

IPC: C07C259/06 , C07D471/04 , C07D417/04 , C07D241/08 , C07D213/56 , C07D233/68 , C07D235/14 , C07D487/10 , C07D471/10 , C07D295/155 , C07D209/44 , A61K31/5377 , A61K31/4439 , A61K31/495 , A61K31/44 , A61K31/417 , A61K31/4184 , A61K31/397 , C07D495/10 , A61K31/407 , A61K31/435 , A61K31/451 , A61K31/4035 , A61K31/277 , A61K31/438 , C07D221/20 , A61K31/185 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14

CPC classification number: C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10 , Y02A50/393 , Y02A50/411 , Y02A50/481

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

8.

发明申请
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS 审中-公开
Title translation: [6,6] FUSED BICYCLIC HDAC8抑制剂

公开(公告)号：US20170066729A1

公开(公告)日：2017-03-09

申请号：US15255817

申请日：2016-09-02

Applicant: Forma Therapeutics, Inc.

Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair

IPC: C07D265/36 , C07D413/06 , C07D401/04 , C07D279/16 , C07D265/34 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D413/12 , C07D491/107

CPC classification number: C07D265/36 , C07D265/34 , C07D279/14 , C07D279/16 , C07D401/04 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D471/04 , C07D487/04 , C07D491/107 , C07D513/04

Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，前药，溶剂合物，水合物，互变异构体或异构体，其中R1，R2，R2'，L，X，W，Y1，Y2，Y3和 Y4。